Miami, FL (PRWEB) February 27, 2016
Global Orthobiologic Inc. an international distributor of regenerative medical products has announced that it has entered into an agreement to become the international distributor for Arteriocyte, a leading clinical stage biotechnology company, whose products include platelet rich plasma (PRP) kits. Of the agreement, Arteriocyte's VP of Sales, Larry Davis said "I am thrilled to be working with Global Orthobiologic and cannot wait to see what we can accomplish together." Until now, Arteriocyte had been focusing their sales and marketing efforts within the United States and this is their first foray into international markets. "The market for regenerative medicine outside of the US is much larger than the US market itself," says Mr. Davis, "there is a lot of room for growth for both our company and our industry."
"PRP is one of the cornerstones of regenerative medicine today. We at Global Orthobiologic are proud to be able to carry Arteriocyte's product portfolio among our catalogue of products," says Randy Beimel of Global Orthbiologic.
Platelet Rich Plasma
Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets. As a concentrated source of autologous platelets, PRP contains (and releases through degranulation) several different growth factors and other cytokines that stimulate healing of bone and soft tissue. PRP was first developed in the 1970s and first used in Italy in 1987 in an open heart surgery procedure. PRP therapy began gaining popularity in the mid 1990s. In humans, PRP has been investigated and used as a clinical tool for several types of medical treatments, including nerve injury, tendinitis, osteoarthritis, cardiac muscle injury, bone repair and regeneration, plastic surgery, and oral surgery. PRP has also received attention in the popular media as a result of its use in treating sports injuries in professional athletes.
About Global Orthobiologic Inc.
Global Orthobiologic, based in Miami Florida, develops, markets, and globally distributes new and innovative products in the field of Regenerative Medicine. Global Orthobiologic was established to promote and distribute groundbreaking medical technologies for use in therapies that significantly enhance the body’s natural healing ability. During the last decade, the company has developed extensive experience in the most advanced medical device industries and technologies. Global Orthobiologic consults not only with startup biotech and medical technology companies, but also with mature companies that wish to better develop their international business. In the past several years, the company's emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies. Global Orthobiologic has built a comprehensive network of experts and country distrubutors in Europe, South America, Middle East, Asia, and Australia. Global Orthobiologic has additional sales offices in Sofia, Bulgaria and Dubai, UAE, as well as a distribution center in Amsterdam, Netherlands.
Arteriocyte, a leading clinical stage biotechnology company, is dedicated to developing novel cellular products and medical devices to help patients heal faster. Arteriocyte leverages its expertise in stem cell and tissue engineering in order to develop a broad portfolio of cell based therapeutics to improve patient outcomes. In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions. Arteriocyte Medical Systems manufactures and distributes the MAGELLAN® Autologous Platelet Separator System.